Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Mechanistic identification of biofluid metabolite changes as markers of acetaminophen-induced liver toxicity in rats.

Pannala VR, Vinnakota KC, Rawls KD, Estes SK, O'Brien TP, Printz RL, Papin JA, Reifman J, Shiota M, Young JD, Wallqvist A.

Toxicol Appl Pharmacol. 2019 Jun 1;372:19-32. doi: 10.1016/j.taap.2019.04.001. Epub 2019 Apr 8.

PMID:
30974156
2.

Network Modeling of Liver Metabolism to Predict Plasma Metabolite Changes During Short-Term Fasting in the Laboratory Rat.

Vinnakota KC, Pannala VR, Wall ML, Rahim M, Estes SK, Trenary I, O'Brien TP, Printz RL, Reifman J, Shiota M, Young JD, Wallqvist A.

Front Physiol. 2019 Mar 1;10:161. doi: 10.3389/fphys.2019.00161. eCollection 2019.

3.

Identification of the Toxicity Pathways Associated With Thioacetamide-Induced Injuries in Rat Liver and Kidney.

Schyman P, Printz RL, Estes SK, Boyd KL, Shiota M, Wallqvist A.

Front Pharmacol. 2018 Nov 6;9:1272. doi: 10.3389/fphar.2018.01272. eCollection 2018.

4.

Metabolic network-based predictions of toxicant-induced metabolite changes in the laboratory rat.

Pannala VR, Wall ML, Estes SK, Trenary I, O'Brien TP, Printz RL, Vinnakota KC, Reifman J, Shiota M, Young JD, Wallqvist A.

Sci Rep. 2018 Aug 3;8(1):11678. doi: 10.1038/s41598-018-30149-7.

5.

Genome-wide gene expression changes associated with exposure of rat liver, heart, and kidney cells to endosulfan.

Liu R, Printz RL, Jenkins EC, O'Brien TP, Te JA, Shiota M, Wallqvist A.

Toxicol In Vitro. 2018 Apr;48:244-254. doi: 10.1016/j.tiv.2018.01.022. Epub 2018 Jan 31.

PMID:
29391264
6.

Insulin's direct hepatic effect explains the inhibition of glucose production caused by insulin secretion.

Edgerton DS, Kraft G, Smith M, Farmer B, Williams PE, Coate KC, Printz RL, O'Brien RM, Cherrington AD.

JCI Insight. 2017 Mar 23;2(6):e91863. doi: 10.1172/jci.insight.91863.

7.

Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle.

O'Brien TP, Jenkins EC, Estes SK, Castaneda AV, Ueta K, Farmer TD, Puglisi AE, Swift LL, Printz RL, Shiota M.

Diabetes. 2017 May;66(5):1172-1184. doi: 10.2337/db16-1410. Epub 2017 Feb 28.

8.

Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation.

Rojas JM, Bruinstroop E, Printz RL, Alijagic-Boers A, Foppen E, Turney MK, George L, Beck-Sickinger AG, Kalsbeek A, Niswender KD.

Mol Metab. 2015 Jan 16;4(3):210-21. doi: 10.1016/j.molmet.2015.01.004. eCollection 2015 Mar.

9.

Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.

Farmer TD, Jenkins EC, O'Brien TP, McCoy GA, Havlik AE, Nass ER, Nicholson WE, Printz RL, Shiota M.

Am J Physiol Endocrinol Metab. 2015 Feb 1;308(3):E206-22. doi: 10.1152/ajpendo.00406.2014. Epub 2014 Dec 16.

10.

Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.

Chen Z, Guo L, Zhang Y, Walzem RL, Pendergast JS, Printz RL, Morris LC, Matafonova E, Stien X, Kang L, Coulon D, McGuinness OP, Niswender KD, Davies SS.

J Clin Invest. 2014 Aug;124(8):3391-406. doi: 10.1172/JCI72517. Epub 2014 Jun 24.

11.

Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis.

Kocalis HE, Hagan SL, George L, Turney MK, Siuta MA, Laryea GN, Morris LC, Muglia LJ, Printz RL, Stanwood GD, Niswender KD.

Mol Metab. 2014 Feb 19;3(4):394-407. doi: 10.1016/j.molmet.2014.01.014. eCollection 2014 Jul.

12.

Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.

Ueta K, O'Brien TP, McCoy GA, Kim K, Healey EC, Farmer TD, Donahue EP, Condren AB, Printz RL, Shiota M.

Am J Physiol Endocrinol Metab. 2014 Jun 1;306(11):E1225-38. doi: 10.1152/ajpendo.00507.2013. Epub 2014 Apr 8.

13.

Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats.

Rojas JM, Stafford JM, Saadat S, Printz RL, Beck-Sickinger AG, Niswender KD.

Am J Physiol Endocrinol Metab. 2012 Dec 15;303(12):E1479-88. doi: 10.1152/ajpendo.00351.2012. Epub 2012 Oct 16.

14.

Neuron-specific deletion of peroxisome proliferator-activated receptor delta (PPARδ) in mice leads to increased susceptibility to diet-induced obesity.

Kocalis HE, Turney MK, Printz RL, Laryea GN, Muglia LJ, Davies SS, Stanwood GD, McGuinness OP, Niswender KD.

PLoS One. 2012;7(8):e42981. doi: 10.1371/journal.pone.0042981. Epub 2012 Aug 20.

15.

Diabetes in Zucker diabetic fatty rat.

Shiota M, Printz RL.

Methods Mol Biol. 2012;933:103-23. doi: 10.1007/978-1-62703-068-7_8.

PMID:
22893404
16.

Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinsulinemia in zucker diabetic fatty rats.

Torres TP, Fujimoto Y, Donahue EP, Printz RL, Houseknecht KL, Treadway JL, Shiota M.

Diabetes. 2011 Sep;60(9):2225-33. doi: 10.2337/db09-1156. Epub 2011 Jul 19.

17.

Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.

Torres TP, Sasaki N, Donahue EP, Lacy B, Printz RL, Cherrington AD, Treadway JL, Shiota M.

J Pharmacol Exp Ther. 2011 Jun;337(3):610-20. doi: 10.1124/jpet.110.177899. Epub 2011 Mar 1.

18.

Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats.

Rojas JM, Printz RL, Niswender KD.

Nutr Diabetes. 2011 Jul 4;1:e10. doi: 10.1038/nutd.2011.6.

19.

The pancreatic islet β-cell-enriched transcription factor Pdx-1 regulates Slc30a8 gene transcription through an intronic enhancer.

Pound LD, Hang Y, Sarkar SA, Wang Y, Milam LA, Oeser JK, Printz RL, Lee CE, Stein R, Hutton JC, O'Brien RM.

Biochem J. 2011 Jan 1;433(1):95-105. doi: 10.1042/BJ20101488.

20.

Genetic and functional assessment of the role of the rs13431652-A and rs573225-A alleles in the G6PC2 promoter that are strongly associated with elevated fasting glucose levels.

Bouatia-Naji N, Bonnefond A, Baerenwald DA, Marchand M, Bugliani M, Marchetti P, Pattou F, Printz RL, Flemming BP, Umunakwe OC, Conley NL, Vaxillaire M, Lantieri O, Balkau B, Marre M, Lévy-Marchal C, Elliott P, Jarvelin MR, Meyre D, Dina C, Oeser JK, Froguel P, O'Brien RM.

Diabetes. 2010 Oct;59(10):2662-71. doi: 10.2337/db10-0389. Epub 2010 Jul 9.

21.

Deletion of the mouse Slc30a8 gene encoding zinc transporter-8 results in impaired insulin secretion.

Pound LD, Sarkar SA, Benninger RK, Wang Y, Suwanichkul A, Shadoan MK, Printz RL, Oeser JK, Lee CE, Piston DW, McGuinness OP, Hutton JC, Powell DR, O'Brien RM.

Biochem J. 2009 Jul 15;421(3):371-6. doi: 10.1042/BJ20090530.

22.

Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet.

Posey KA, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan-Giri A, Pennathur S, Baskin DG, Heinecke JW, Woods SC, Schwartz MW, Niswender KD.

Am J Physiol Endocrinol Metab. 2009 May;296(5):E1003-12. doi: 10.1152/ajpendo.90377.2008. Epub 2008 Dec 30.

23.

Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats.

Torres TP, Catlin RL, Chan R, Fujimoto Y, Sasaki N, Printz RL, Newgard CB, Shiota M.

Diabetes. 2009 Jan;58(1):78-86. doi: 10.2337/db08-1119. Epub 2008 Oct 24.

24.

Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis.

Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW.

Endocrinology. 2009 Feb;150(2):707-12. doi: 10.1210/en.2008-0899. Epub 2008 Oct 9.

25.

Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.

Fyfe MC, White JR, Taylor A, Chatfield R, Wargent E, Printz RL, Sulpice T, McCormack JG, Procter MJ, Reynet C, Widdowson PS, Wong-Kai-In P.

Diabetologia. 2007 Jun;50(6):1277-87. Epub 2007 Apr 6.

PMID:
17415548
26.

Tweaking the glucose sensor: adjusting glucokinase activity with activator compounds.

Printz RL, Granner DK.

Endocrinology. 2005 Sep;146(9):3693-5. Review. No abstract available.

PMID:
16105828
27.

Control of glucose phosphorylation in L6 myotubes by compartmentalization, hexokinase, and glucose transport.

Whitesell RR, Ardehali H, Printz RL, Beechem JM, Knobel SM, Piston DW, Granner DK, Van Der Meer W, Perriott LM, May JM.

Biochem J. 2003 Feb 15;370(Pt 1):47-56.

28.

Role of Ca(2+) fluctuations in L6 myotubes in the regulation of the hexokinase II gene.

Halseth AE, O'Doherty RM, Printz RL, Bracy DP, Granner DK, Wasserman DH.

J Appl Physiol (1985). 2000 Feb;88(2):669-73.

29.

Human ZHX1: cloning, chromosomal location, and interaction with transcription factor NF-Y.

Yamada K, Printz RL, Osawa H, Granner DK.

Biochem Biophys Res Commun. 1999 Aug 11;261(3):614-21.

PMID:
10441475
30.

Functional interaction between the N- and C-terminal halves of human hexokinase II.

Ardehali H, Printz RL, Whitesell RR, May JM, Granner DK.

J Biol Chem. 1999 Jun 4;274(23):15986-9.

31.

Isolation and characterization of the mouse cytosolic phosphoenolpyruvate carboxykinase (GTP) gene: evidence for tissue-specific hypersensitive sites.

Williams CP, Postic C, Robin D, Robin P, Parrinello J, Shelton K, Printz RL, Magnuson MA, Granner DK, Forest C, Chalkley R.

Mol Cell Endocrinol. 1999 Feb 25;148(1-2):67-77.

PMID:
10221772
32.

Hexokinase II gene: structure, regulation and promoter organization.

Printz RL, Osawa H, Ardehali H, Koch S, Granner DK.

Biochem Soc Trans. 1997 Feb;25(1):107-12. Review. No abstract available.

PMID:
9056853
33.
34.

Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin.

Osawa H, Sutherland C, Robey RB, Printz RL, Granner DK.

J Biol Chem. 1996 Jul 12;271(28):16690-4.

35.

Overexpression of hexokinase II in transgenic mice. Evidence that increased phosphorylation augments muscle glucose uptake.

Chang PY, Jensen J, Printz RL, Granner DK, Ivy JL, Moller DE.

J Biol Chem. 1996 Jun 21;271(25):14834-9.

36.

A novel (TA)n polymorphism in the hexokinase II gene: application to noninsulin-dependent diabetes mellitus in the Pima Indians.

Ardehali H, Tiller GE, Printz RL, Mochizuki H, Prochazka M, Granner DK.

Hum Genet. 1996 Apr;97(4):482-5.

PMID:
8834247
37.

Variant sequences of the Hexokinase II gene in familial NIDDM.

Taylor RW, Printz RL, Armstrong M, Granner DK, Alberti KG, Turnbull DM, Walker M.

Diabetologia. 1996 Mar;39(3):322-8.

PMID:
8721778
38.

Examination of the phosphoenolpyruvate carboxykinase gene promoter in patients with noninsulin-dependent diabetes mellitus.

Ludwig DS, Vidal-Puig A, O'Brien RM, Printz RL, Granner DK, Moller DE, Flier JS.

J Clin Endocrinol Metab. 1996 Feb;81(2):503-6.

PMID:
8636258
39.

Functional organization of mammalian hexokinase II. Retention of catalytic and regulatory functions in both the NH2- and COOH-terminal halves.

Ardehali H, Yano Y, Printz RL, Koch S, Whitesell RR, May JM, Granner DK.

J Biol Chem. 1996 Jan 26;271(4):1849-52.

40.

Transient gene transfer into myotubes following differentiation in culture.

Robey RB, Osawa H, Printz RL, Granner DK.

Biotechniques. 1996 Jan;20(1):40-2. No abstract available.

41.

Identification of the aminoacid polymorphisms in hexokinase II in Japanese subjects.

Shimada F, Hashimoto N, Kanatsuka A, Printz RL, Granner DK, Makino H.

Diabetologia. 1996 Jan;39(1):123-4. No abstract available.

PMID:
8720614
42.

Structural and functional analysis of the human phosphoenolpyruvate carboxykinase gene promoter.

O'Brien RM, Printz RL, Halmi N, Tiesinga JJ, Granner DK.

Biochim Biophys Acta. 1995 Dec 27;1264(3):284-8.

PMID:
8547315
43.

Regulation of hexokinase II gene transcription and glucose phosphorylation by catecholamines, cyclic AMP, and insulin.

Osawa H, Printz RL, Whitesell RR, Granner DK.

Diabetes. 1995 Dec;44(12):1426-32.

PMID:
7589850
44.

Expression cloning of a zinc-finger cyclic AMP-response-element-binding protein.

O'Brien RM, Halmi N, Stromstedt PE, Printz RL, Granner DK.

Biochem J. 1995 Nov 15;312 ( Pt 1):17-21.

45.

Isolation, characterization and chromosomal localization of a human pseudogene for hexokinase II.

Ardehali H, Printz RL, Koch S, Phillips JA 3rd, Granner DK.

Gene. 1995 Oct 27;164(2):357-61.

PMID:
7590357
46.

Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle.

Mandarino LJ, Printz RL, Cusi KA, Kinchington P, O'Doherty RM, Osawa H, Sewell C, Consoli A, Granner DK, DeFronzo RA.

Am J Physiol. 1995 Oct;269(4 Pt 1):E701-8. Erratum in: Am J Physiol 1996 Jan;270(1 Pt 1):section E followi.

PMID:
7485484
47.

Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity.

Echwald SM, Bjørbaek C, Hansen T, Clausen JO, Vestergaard H, Zierath JR, Printz RL, Granner DK, Pedersen O.

Diabetes. 1995 Mar;44(3):347-53.

PMID:
7883123
48.

Analysis of the hexokinase II gene in subjects with insulin resistance and NIDDM and detection of a Gln142-->His substitution.

Vidal-Puig A, Printz RL, Stratton IM, Granner DK, Moller DE.

Diabetes. 1995 Mar;44(3):340-6.

PMID:
7883122
49.

Human hexokinase II mRNA and gene structure.

Printz RL, Ardehali H, Koch S, Granner DK.

Diabetes. 1995 Mar;44(3):290-4.

PMID:
7883116
50.

Coexpression of glucose transporters and glucokinase in Xenopus oocytes indicates that both glucose transport and phosphorylation determine glucose utilization.

Morita H, Yano Y, Niswender KD, May JM, Whitesell RR, Wu L, Printz RL, Granner DK, Magnuson MA, Powers AC.

J Clin Invest. 1994 Oct;94(4):1373-82.

Supplemental Content

Loading ...
Support Center